The Oral Capsule- the Most Appropriate Dosage Form for Croton Membranaceus

Recent studies have provided relevant scientific support for the use of C. membranaceus root in the treatment of prostate cancers. In the current study, we formulated both liquid and solid oral dosage forms from the ethanol extract of C. membranaceus root and investigated their physicochemical properties, release effects and suitability in comparison with the currently used aqueous decoctions and directly powdered plant material, in order to determine the most appropriate and suitable dosage form that will maximize the benefits of therapy with this species. The prepared solution from the ethanol extract had characteristics similar to the aqueous decoction, but unlike the later, it maintained its specifications and stability throughout the period of study. However, the use of large volumes, convenience and suitability for long term use, will limit their application. The assessed properties of the prepared tablets and capsules met all the specifications required for good quality and they can be used in simple and convenient doses of one tablet or capsule, three times a day, in place of unstable decoctions and large volume solutions. The in vitro release profile of the capsules was however, better (98.8±1.3 % after 45 minutes) and significantly higher (P<0.01) than that of the tablets (85.2±1.6 %), and with the protection of the extract from light and masking of unwanted color and taste as added advantages, the oral capsules should be the preferred choice of solid dosage form for C. membranaceus. The capsules of the direct plant material had active content (2.8±1.4 mg) and in vitro cumulative release after 45 minutes (42.0±2.6 %) lower and significantly different (P<0.01) from those of the tablets and capsules prepared with the extract. The results strongly support the assertions that the formulation of suitable and appropriate herbal remedies from plant extracts may be more desirable, advantageous and therapeutically more beneficial than incorporating the direct plant materials, and that the oral capsule of C. membranaceus root extract will ensure compliance and maximize therapeutic outcomes.